ReviewClinical microbiology reviews1999
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.
Review in Clinical microbiology reviews, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 104 citations in OpenAlex.
- Discovery of globally rare CYP51 mutations associated with azole resistance in Iranian Zymoseptoria tritici isolates.BMC plant biology · 2025Article
- Synthesis and Biological Activity of Ultrashort Antimicrobial Peptides Bearing a Non-Coded Amino Acid.Journal of peptide science : an official publication of the European Peptide Society · 2025Article
- Antifungal mechanism of volatile compounds emitted bymSphere · 2023Article
- Antifungal Siderophore Conjugates for Theranostic Applications in Invasive Pulmonary Aspergillosis Using Low-Molecular TAFC Scaffolds.Journal of fungi (Basel, Switzerland) · 2021Article
- 'Acridines' as New Horizons in Antifungal Treatment.Molecules (Basel, Switzerland) · 2020Review
- The antifungal pipeline: a reality check.Nature reviews. Drug discovery · 2017Review
- Genome-Wide Screen RevealsG3 (Bethesda, Md.) · 2017Article
- Increasing the Fungicidal Action of Amphotericin B by Inhibiting the Nitric Oxide-Dependent Tolerance Pathway.Oxidative medicine and cellular longevity · 2017Article
- Thermodynamic Analysis of the Geldanamycin-Hsp90 Interaction in a Whole Cell Lysate Using a Mass Spectrometry-Based Proteomics Approach.Journal of the American Society for Mass Spectrometry · 2016Article
- Reverse Chemical Genetics: Comprehensive Fitness Profiling Reveals the Spectrum of Drug Target Interactions.PLoS genetics · 2016Article
- Computational approaches to natural product discovery.Nature chemical biology · 2015Article
- Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.Antimicrobial agents and chemotherapy · 2015Article
- The genome of tolypocladium inflatum: evolution, organization, and expression of the cyclosporin biosynthetic gene cluster.PLoS genetics · 2013Article
- Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review.Pharmacology & therapeutics · 2013Review
- Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin.Molecular and cellular biochemistry · 2013Article
- Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae.Journal of bioenergetics and biomembranes · 2012Article
- Review
- Prediction of N-myristoylation modification of proteins by SVM.Bioinformation · 2011Article
- Virtual prototyping study shows increased ATPase activity of Hsp90 to be the key determinant of cancer phenotype.Systems and synthetic biology · 2010Article
- Rapamycin inhibits yeast nucleotide excision repair independently of tor kinases.Toxicological sciences : an official journal of the Society of Toxicology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Recent evolutionary studies reveal that microorganisms including yeasts and fungi are more closely related to mammals than was previously appreciated. Possibly as a consequence, many natural-product toxins that have antimicrobial activity are also toxic to mammalian cells. While this makes it difficult to discover antifungal agents without toxic side effects, it also has enabled detailed studies of drug action in simple genetic model systems. We review here studies on the antifungal actions of antineoplasmic agents. Topics covered include the mechanisms of action of inhibitors of topoisomerases I and II; the immunosuppressants rapamycin, cyclosporin A, and FK506; the phosphatidylinositol 3-kinase inhibitor wortmannin; the angiogenesis inhibitors fumagillin and ovalicin; the HSP90 inhibitor geldanamycin; and agents that inhibit sphingolipid metabolism. In general, these natural products inhibit target proteins conserved from microorganisms to humans. These studies highlight the potential of microorganisms as screening tools to elucidate the mechanisms of action of novel pharmacological agents with unique effects against specific mammalian cell types, including neoplastic cells. In addition, this analysis suggests that antineoplastic agents and derivatives might find novel indications in the treatment of fungal infections, for which few agents are presently available, toxicity remains a serious concern, and drug resistance is emerging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.